Neurokinin B and NK3/TACR3: a laboratory signaling and trafficking guide

1) Qualify the NKB reagent before biology

Mature human NKB is the amidated decapeptide Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH₂. The amidated C terminus belongs to the native pharmacophore and must be specified explicitly. Record sequence, terminal chemistry, counterion, stated chromatographic purity, peptide-content basis, residual water, lot, and storage history. A weighed amount of lyophilizate is not automatically the same amount of peptide because salts, water, and residual solvent contribute mass.

Verify intact mass and chromatographic purity before receptor experiments. NKB contains two methionines, so oxidation products deserve particular attention. Confirm the working solution in the actual assay matrix where practical, and include low-concentration recovery tests to reveal adsorption to tubes, tips, or plates. If a fluorophore, radioisotope, linker, or non-native residue is introduced, qualify that derivative as a separate ligand by comparing its affinity and efficacy with unmodified amidated NKB.

NKB shares the conserved tachykinin C-terminal motif with substance P and neurokinin A. This structural relationship explains overlapping receptor pharmacology. Early recombinant work showed that cell context itself can alter apparent NK3 binding: rat NK3 expressed stably in CHO cells showed lower agonist affinity than the same receptor transiently expressed in COS-7 cells, even though the rank-order specificity remained consistent with an NK3 phenotype.^[1] Expression system and membrane environment therefore belong in the experimental record, not just the methods footnote.

2) Establish NK3/TACR3 causality

Use the same parental cell background to express sequence-verified NK1, NK2, and NK3 separately. Quantify surface receptor abundance rather than normalizing by plasmid amount or total receptor protein. Run complete NKB concentration-response curves in all three lines, alongside subtype-selective reference agonists. Include parental cells to detect endogenous tachykinin receptors or non-receptor effects. Senktide is useful as an NK3-preferring comparator, but it is not a substitute for testing native NKB.

In a native model, combine TACR3 knockout or knockdown with controlled rescue. Demonstrate that TACR3 loss removes the NKB response while leaving an unrelated Gq-coupled receptor intact. Rescue should restore the response at an expression level comparable to the native system. Antagonists can provide convergent evidence, but their selectivity must be established at NK1 and NK2 under the same assay conditions. High antagonist concentrations can erase nominal subtype selectivity.

Human NK3 variants provide useful mechanistic controls. A His148Leu substitution in the first extracellular loop produced profoundly impaired calcium signaling in a heterologous assay: wild-type NK3 responded to NKB at low nanomolar concentration, whereas the mutant required micromolar NKB for a detectable response.^[2] Other TACR3 variants have separated trafficking, ligand binding, and G-protein activation. Y256H and Y315C reduced whole-cell or surface receptor abundance and nearly eliminated inositol-phosphate signaling, while R295S retained ligand interaction but impaired Gq-subunit dissociation in a FRET assay.^[3] These findings show why a failed response cannot be interpreted without measuring receptor localization and abundance.

3) Resolve proximal signaling and kinetics

NK3 classically couples to Gq/11, phospholipase C, inositol phosphate production, and intracellular calcium release. Calcium dyes are convenient but highly amplified: peak height depends on receptor reserve, dye loading, store content, extracellular calcium, and acquisition rate. Preserve and report the full trace, not only a fitted EC50. Pair calcium with a proximal endpoint such as Gq activation, PLC activity, or IP1 accumulation.

Native human airway smooth-muscle experiments detected NK1, NK2, and NK3 transcripts and proteins. The NK3-selective agonist senktide increased inositol phosphate and intracellular calcium in native and receptor-overexpressing cells, supporting functional Gq coupling in that system.^[4] The initial calcium phase was linked primarily to release from intracellular stores, whereas a sustained component reflected extracellular entry. Experiments intended to distinguish these mechanisms should include calcium-free buffer, add-back conditions, and validated controls for store-operated entry.

Use time courses for ERK phosphorylation, transcriptional reporters, and other distal readouts. These endpoints integrate receptor activation with feedback, receptor internalization, and pathway cross-talk. Vehicle, reference agonist, parental cells, an unrelated Gq agonist, and a viability or cell-number control are minimum safeguards. For any functional-selectivity claim, estimate affinity and efficacy across multiple proximal pathways at comparable receptor density rather than comparing raw EC50 values from unrelated assay formats.

Desensitization should be measured explicitly. Apply a defined first pulse, wash under validated conditions, then deliver a second pulse over a recovery time course. Track ligand carryover and receptor surface return in parallel. A smaller second calcium peak can arise from receptor desensitization, incomplete ligand removal, store depletion, or altered cell health; calcium alone cannot discriminate among these explanations.

4) Separate binding from amplified function

Saturation binding with a qualified NKB-derived tracer can estimate apparent affinity and receptor-site density. Define nonspecific binding with excess unlabeled ligand, test receptor-free membranes, and demonstrate that incubation approaches equilibrium. For competition experiments, include native NKB, substance P, NKA, senktide, and subtype-selective reference ligands. Convert IC50 to Ki only when competitive equilibrium assumptions and tracer concentration are appropriate.

Chimeric NK1/NK3 receptor studies found that NKB and substance P recognition changed progressively as multiple receptor segments were exchanged, indicating that natural tachykinins contact several receptor determinants. Senktide behaved differently: its recognition depended strongly on the presence of NK3 transmembrane segments III and IV.^[5] Consequently, agreement between NKB and senktide responses supports NK3 attribution, but the two ligands should not be assumed to probe identical receptor contacts or active conformations.

Report pKi or Kd together with pEC50, maximal response, Hill slope, and measured receptor density. An apparently potent functional response can occur at modest occupancy when receptor reserve is high, while a low-amplification assay may make the same ligand look weaker. Likewise, a tagged receptor may traffic correctly yet have altered binding. Validate receptor tags and ligand labels independently before using them in mechanistic experiments.

5) Quantify NK3 trafficking and resensitization

NK3 regulation differs from the prolonged arrestin engagement often observed with NK1. In cells comparing the two receptors, NK3 interacted transiently with β-arrestin2 at the plasma membrane, internalized, activated MAP kinase, and resensitized more rapidly than NK1. Swapping intracellular loop 3 and the C-terminal tail transferred key aspects of arrestin interaction and resensitization behavior, identifying those receptor regions as regulatory determinants.^[6]

Measure surface loss and recycling with at least two orthogonal methods—for example, an extracellular epitope assay plus imaging or acid-wash separation of surface and internalized tracer. Acquire early points for arrestin recruitment and later points for endosomal trafficking and surface recovery. β-arrestin biosensors should be titrated because overexpression can change the process being measured.

Co-expression creates another confounder. In cells and enteric neurons containing NK1 and NK3, prior NK1 activation sequestered arrestins and inhibited NK3 endocytosis and homologous desensitization; increasing β-arrestin1 rescued NK3 endocytosis. NK3 activation did not produce the reciprocal effect on NK1.^[7] Thus, a native cell's NK3 trafficking phenotype may depend on recent activation of a different tachykinin receptor. Single-receptor reconstitution should establish the baseline before defined co-expression or sequential-ligand studies.

Keep ligand integrity connected to trafficking measurements. A declining extracellular NKB concentration, oxidative modification, or proteolysis can mimic rapid desensitization, while retained ligand can delay apparent recovery. Analyze samples at the beginning and end of the exposure window by LC–MS when the matrix is proteolytically active, and test recovery from all contact materials.

6) A reproducible NKB–NK3 workflow

1. Qualify NKB. Confirm amidation, intact mass, purity, concentration basis, oxidation state, and matrix recovery.
2. Calibrate the receptor panel. Measure NK1, NK2, and NK3 surface abundance and reference-ligand responses.
3. Measure orthogonal endpoints. Pair binding with proximal Gq or IP1 and time-resolved calcium.
4. Prove causality. Use TACR3 loss and rescue in the native model.
5. Resolve receptor regulation. Quantify arrestin recruitment, internalization, recycling, and second-pulse recovery.
6. Preserve replicate structure. Report independent cultures, passages, peptide lots, and technical wells separately.

The interpretable unit is a chemically verified NKB preparation tested across a quantified tachykinin-receptor panel, with TACR3 causality, proximal signaling, and receptor trafficking measured on appropriate time scales. This design separates NK3 pharmacology from tachykinin cross-reactivity, expression artifacts, amplified calcium signals, and arrestin competition between co-expressed receptors.